Preeclampsia risk assessment across all trimesters using blood-based biochemical markers

Hear from our subject matter experts about the latest breakthrough biomarkers to help in the risk assessment and clinical management of preeclampsia across U.S. patient populations across all trimesters.

Q&A with a Preeclampsia Expert: Dr. Strickland Answers Top Questions

Understanding the signs and symptoms of preeclampsia, combined with routine screening, can save lives.

ACMG Annual Clinical Genetics Meeting

Toronto, Canada

Integrating technologies: Ultrasound and cfDNA screening in twin pregnancies

Despite overall limited data on cell-free DNA (cfDNA) testing in twin gestations, MaterniT 21 PLUS has demonstrated high sensitivity and specificity in screening for trisomy 21 in twins from the first trimester of pregnancy (comparable to that observed in singleton pregnancies), as well as promising performance in screening for trisomies 13 and 18, according to the results of a newly published study.1 Hear from our experts about the nuances of twin pregnancy care as we combine ultrasound expertise with the latest research review on fetal cfDNA screening.